Janssen-Cilag Ltd.
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT03998683
- Locations
- 🇩🇪
Fachklinik Bad Bentheim, Bad Bentheim, Germany
🇩🇪University Hospital Dresden, Dresden, Germany
🇫🇷Hopital Charles Nicolle, Rouen, France
A Registry Study of Participants With Multiple Myeloma in Latin America
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 2059
- Registration Number
- NCT03955900
- Locations
- 🇧🇷
Fundacao para o Desenvolvimento Medico Hospitalar (UNESP Botucatu), Botucatu, Brazil
🇦🇷Fundaleu, Buenos Aires, Argentina
🇦🇷Instituto de Oncologia Angel H. Roffo, Buenos Aires, Argentina
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 215
- Registration Number
- NCT03782376
- Locations
- 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇫🇷CHRU Montpellier - Hopital Saint-Eloi, Montpellier, France
🇩🇪Hamburgisches Forschungsinstitut fuer CED, HaFCED e.K., Hamburg, Germany
Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT03495973
- Locations
- 🇸🇪
Universitetssjukhuset Örebro, Örebro, Sweden
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 508
- Registration Number
- NCT03425591
Treatment-Resistant Depression Cohort in Europe
- Conditions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 830
- Registration Number
- NCT03373253
- Locations
- 🇪🇸
Hosp. Univ. de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
🇪🇸Centro de Salud Mental Toscar, Elche, Spain
🇪🇸Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT03107793
- Locations
- 🇳🇱
AMC, Amsterdam, Netherlands
🇵🇹Centro Hospitalar de Tondela Viseu, EPE, Viseu, Portugal
🇸🇰Gastroenterology Center ASSIDUO, Bratislava, Slovakia
Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia
- Conditions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 364
- Registration Number
- NCT02874560
Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil
- Conditions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 1649
- Registration Number
- NCT02773394
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT02713282